- Home
- ITRM vs VRCA Comparison
ITRM vs VRCA Comparison
Compare ITRM & VRCA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ITRM
- VRCA
- Stock Information
- Founded
- ITRM 2015
- VRCA 2013
- Country
- ITRM Ireland
- VRCA United States
- Employees
- ITRM N/A
- VRCA N/A
- Industry
- ITRM Biotechnology: Pharmaceutical Preparations
- VRCA Biotechnology: Pharmaceutical Preparations
- Sector
- ITRM Health Care
- VRCA Health Care
- Exchange
- ITRM Nasdaq
- VRCA Nasdaq
- Market Cap
- ITRM 40.0M
- VRCA 40.6M
- IPO Year
- ITRM 2018
- VRCA 2018
- Fundamental
- Price
- ITRM $0.77
- VRCA $4.63
- Analyst Decision
- ITRM Strong Buy
- VRCA Hold
- Analyst Count
- ITRM 1
- VRCA 5
- Target Price
- ITRM $9.00
- VRCA $60.00
- AVG Volume (30 Days)
- ITRM 739.9K
- VRCA 520.1K
- Earning Date
- ITRM 11-13-2025
- VRCA 11-03-2025
- Dividend Yield
- ITRM N/A
- VRCA N/A
- EPS Growth
- ITRM N/A
- VRCA N/A
- EPS
- ITRM N/A
- VRCA N/A
- Revenue
- ITRM N/A
- VRCA $14,704,000.00
- Revenue This Year
- ITRM N/A
- VRCA $332.45
- Revenue Next Year
- ITRM $482.25
- VRCA $12.85
- P/E Ratio
- ITRM N/A
- VRCA N/A
- Revenue Growth
- ITRM N/A
- VRCA 5.72
- 52 Week Low
- ITRM $0.61
- VRCA $3.82
- 52 Week High
- ITRM $3.02
- VRCA $17.38
- Technical
- Relative Strength Index (RSI)
- ITRM 59.02
- VRCA 48.70
- Support Level
- ITRM $0.66
- VRCA $4.17
- Resistance Level
- ITRM $0.81
- VRCA $4.75
- Average True Range (ATR)
- ITRM 0.05
- VRCA 0.34
- MACD
- ITRM 0.01
- VRCA 0.06
- Stochastic Oscillator
- ITRM 63.76
- VRCA 69.04
About ITRM Iterum Therapeutics plc
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.
About VRCA Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.